Redox Biol:研究证实线粒体功能障碍对于帕金森综合征的发展起到重要作用

2017-11-18 Emma MedSci原创

帕金森病(PD)是常见的神经退行性疾病之一。临床症状为:运动过缓、肌强直、静止性震颤、姿势步态异常,认知/精神异常、睡眠障碍、自主神经功能障碍、感觉障碍。

帕金森病(PD)是常见的神经退行性疾病之一。临床症状为:运动过缓、肌强直、静止性震颤、姿势步态异常,认知/精神异常、睡眠障碍、自主神经功能障碍、感觉障碍。帕金森病(PD)患者中散发病例占90-95%。非典型帕金森综合征占所有帕金森综合征患者的约20%。进行性核上性麻痹(PSP)属于非典型帕金森病,在组织病理学上被分类为tau蛋白病。

研究发现,PSP患者骨髓的间充质干细胞(MSCs)出现线粒体功能障碍,包括较高的线粒体降解基础率、较低的生物发生水平以及线粒体质量减少。并且出现膜电位降低、NADH依赖性呼吸受抑制以及ROS产生、氧化应激显著增加和细胞主要的抗氧化剂GSH减少。由于脂肪细胞活动主要依靠线粒体代谢提供的生物能量,所以PSP-MSC通过损坏线粒体功能,导致MSCs向脂肪细胞分化发生障碍,此外还在试验中检测到细胞中脂滴形成受到显著损害。在转录水平上,涉及脂肪形成分子网络的两个关键基因PPARγ和FABP4表达显著降低。

PSP-MSC中的发现为"特发性"帕金森病的病因学提供了新的见解,并证实了线粒体功能障碍对于帕金森综合征的发展起到重要作用,而这种作用似乎与细胞类型无关。

原始出处:
Angelova PR, et al. Mitochondrial dysfunction in Parkinsonian mesenchymal stem cells impairs differentiation. Redox Biol. 2017 Oct 20;14:474-484. doi: 10.1016/j.redox.2017.10.016.

本文系梅斯医学(MedSci)原创翻译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1677180, encodeId=7dff16e718071, content=<a href='/topic/show?id=d31ce7585bb' target=_blank style='color:#2F92EE;'>#线粒体功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77585, encryptionId=d31ce7585bb, topicName=线粒体功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=92f027457982, createdName=xuruicheng, createdTime=Sun Dec 10 05:39:00 CST 2017, time=2017-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665725, encodeId=3a9c1665e25ed, content=<a href='/topic/show?id=de2a485385f' target=_blank style='color:#2F92EE;'>#帕金森综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48538, encryptionId=de2a485385f, topicName=帕金森综合征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43d925986347, createdName=12498f1em16(暂无昵称), createdTime=Fri Dec 15 01:39:00 CST 2017, time=2017-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917789, encodeId=1d37191e78937, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Mar 02 10:39:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2023497, encodeId=7122202349e86, content=<a href='/topic/show?id=57ce9605ef6' target=_blank style='color:#2F92EE;'>#重要作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96057, encryptionId=57ce9605ef6, topicName=重要作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Tue May 01 00:39:00 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767325, encodeId=78b31e673255a, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Sun Apr 01 15:39:00 CST 2018, time=2018-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421122, encodeId=64c71421122f0, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Mon Nov 20 07:39:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431017, encodeId=f8cf143101e5b, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Mon Nov 20 07:39:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1603573, encodeId=8d2616035e355, content=<a href='/topic/show?id=83d1e7588bb' target=_blank style='color:#2F92EE;'>#线粒体功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77588, encryptionId=83d1e7588bb, topicName=线粒体功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=927419051757, createdName=ylz8409, createdTime=Mon Nov 20 07:39:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262405, encodeId=c36a262405a6, content=帕金森与线粒体功能障碍, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Sun Nov 19 00:50:56 CST 2017, time=2017-11-19, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1677180, encodeId=7dff16e718071, content=<a href='/topic/show?id=d31ce7585bb' target=_blank style='color:#2F92EE;'>#线粒体功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77585, encryptionId=d31ce7585bb, topicName=线粒体功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=92f027457982, createdName=xuruicheng, createdTime=Sun Dec 10 05:39:00 CST 2017, time=2017-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665725, encodeId=3a9c1665e25ed, content=<a href='/topic/show?id=de2a485385f' target=_blank style='color:#2F92EE;'>#帕金森综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48538, encryptionId=de2a485385f, topicName=帕金森综合征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43d925986347, createdName=12498f1em16(暂无昵称), createdTime=Fri Dec 15 01:39:00 CST 2017, time=2017-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917789, encodeId=1d37191e78937, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Mar 02 10:39:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2023497, encodeId=7122202349e86, content=<a href='/topic/show?id=57ce9605ef6' target=_blank style='color:#2F92EE;'>#重要作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96057, encryptionId=57ce9605ef6, topicName=重要作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Tue May 01 00:39:00 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767325, encodeId=78b31e673255a, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Sun Apr 01 15:39:00 CST 2018, time=2018-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421122, encodeId=64c71421122f0, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Mon Nov 20 07:39:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431017, encodeId=f8cf143101e5b, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Mon Nov 20 07:39:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1603573, encodeId=8d2616035e355, content=<a href='/topic/show?id=83d1e7588bb' target=_blank style='color:#2F92EE;'>#线粒体功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77588, encryptionId=83d1e7588bb, topicName=线粒体功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=927419051757, createdName=ylz8409, createdTime=Mon Nov 20 07:39:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262405, encodeId=c36a262405a6, content=帕金森与线粒体功能障碍, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Sun Nov 19 00:50:56 CST 2017, time=2017-11-19, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1677180, encodeId=7dff16e718071, content=<a href='/topic/show?id=d31ce7585bb' target=_blank style='color:#2F92EE;'>#线粒体功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77585, encryptionId=d31ce7585bb, topicName=线粒体功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=92f027457982, createdName=xuruicheng, createdTime=Sun Dec 10 05:39:00 CST 2017, time=2017-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665725, encodeId=3a9c1665e25ed, content=<a href='/topic/show?id=de2a485385f' target=_blank style='color:#2F92EE;'>#帕金森综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48538, encryptionId=de2a485385f, topicName=帕金森综合征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43d925986347, createdName=12498f1em16(暂无昵称), createdTime=Fri Dec 15 01:39:00 CST 2017, time=2017-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917789, encodeId=1d37191e78937, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Mar 02 10:39:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2023497, encodeId=7122202349e86, content=<a href='/topic/show?id=57ce9605ef6' target=_blank style='color:#2F92EE;'>#重要作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96057, encryptionId=57ce9605ef6, topicName=重要作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Tue May 01 00:39:00 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767325, encodeId=78b31e673255a, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Sun Apr 01 15:39:00 CST 2018, time=2018-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421122, encodeId=64c71421122f0, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Mon Nov 20 07:39:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431017, encodeId=f8cf143101e5b, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Mon Nov 20 07:39:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1603573, encodeId=8d2616035e355, content=<a href='/topic/show?id=83d1e7588bb' target=_blank style='color:#2F92EE;'>#线粒体功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77588, encryptionId=83d1e7588bb, topicName=线粒体功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=927419051757, createdName=ylz8409, createdTime=Mon Nov 20 07:39:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262405, encodeId=c36a262405a6, content=帕金森与线粒体功能障碍, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Sun Nov 19 00:50:56 CST 2017, time=2017-11-19, status=1, ipAttribution=)]
    2018-03-02 sunylz
  4. [GetPortalCommentsPageByObjectIdResponse(id=1677180, encodeId=7dff16e718071, content=<a href='/topic/show?id=d31ce7585bb' target=_blank style='color:#2F92EE;'>#线粒体功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77585, encryptionId=d31ce7585bb, topicName=线粒体功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=92f027457982, createdName=xuruicheng, createdTime=Sun Dec 10 05:39:00 CST 2017, time=2017-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665725, encodeId=3a9c1665e25ed, content=<a href='/topic/show?id=de2a485385f' target=_blank style='color:#2F92EE;'>#帕金森综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48538, encryptionId=de2a485385f, topicName=帕金森综合征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43d925986347, createdName=12498f1em16(暂无昵称), createdTime=Fri Dec 15 01:39:00 CST 2017, time=2017-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917789, encodeId=1d37191e78937, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Mar 02 10:39:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2023497, encodeId=7122202349e86, content=<a href='/topic/show?id=57ce9605ef6' target=_blank style='color:#2F92EE;'>#重要作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96057, encryptionId=57ce9605ef6, topicName=重要作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Tue May 01 00:39:00 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767325, encodeId=78b31e673255a, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Sun Apr 01 15:39:00 CST 2018, time=2018-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421122, encodeId=64c71421122f0, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Mon Nov 20 07:39:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431017, encodeId=f8cf143101e5b, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Mon Nov 20 07:39:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1603573, encodeId=8d2616035e355, content=<a href='/topic/show?id=83d1e7588bb' target=_blank style='color:#2F92EE;'>#线粒体功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77588, encryptionId=83d1e7588bb, topicName=线粒体功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=927419051757, createdName=ylz8409, createdTime=Mon Nov 20 07:39:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262405, encodeId=c36a262405a6, content=帕金森与线粒体功能障碍, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Sun Nov 19 00:50:56 CST 2017, time=2017-11-19, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1677180, encodeId=7dff16e718071, content=<a href='/topic/show?id=d31ce7585bb' target=_blank style='color:#2F92EE;'>#线粒体功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77585, encryptionId=d31ce7585bb, topicName=线粒体功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=92f027457982, createdName=xuruicheng, createdTime=Sun Dec 10 05:39:00 CST 2017, time=2017-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665725, encodeId=3a9c1665e25ed, content=<a href='/topic/show?id=de2a485385f' target=_blank style='color:#2F92EE;'>#帕金森综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48538, encryptionId=de2a485385f, topicName=帕金森综合征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43d925986347, createdName=12498f1em16(暂无昵称), createdTime=Fri Dec 15 01:39:00 CST 2017, time=2017-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917789, encodeId=1d37191e78937, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Mar 02 10:39:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2023497, encodeId=7122202349e86, content=<a href='/topic/show?id=57ce9605ef6' target=_blank style='color:#2F92EE;'>#重要作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96057, encryptionId=57ce9605ef6, topicName=重要作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Tue May 01 00:39:00 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767325, encodeId=78b31e673255a, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Sun Apr 01 15:39:00 CST 2018, time=2018-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421122, encodeId=64c71421122f0, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Mon Nov 20 07:39:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431017, encodeId=f8cf143101e5b, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Mon Nov 20 07:39:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1603573, encodeId=8d2616035e355, content=<a href='/topic/show?id=83d1e7588bb' target=_blank style='color:#2F92EE;'>#线粒体功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77588, encryptionId=83d1e7588bb, topicName=线粒体功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=927419051757, createdName=ylz8409, createdTime=Mon Nov 20 07:39:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262405, encodeId=c36a262405a6, content=帕金森与线粒体功能障碍, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Sun Nov 19 00:50:56 CST 2017, time=2017-11-19, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1677180, encodeId=7dff16e718071, content=<a href='/topic/show?id=d31ce7585bb' target=_blank style='color:#2F92EE;'>#线粒体功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77585, encryptionId=d31ce7585bb, topicName=线粒体功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=92f027457982, createdName=xuruicheng, createdTime=Sun Dec 10 05:39:00 CST 2017, time=2017-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665725, encodeId=3a9c1665e25ed, content=<a href='/topic/show?id=de2a485385f' target=_blank style='color:#2F92EE;'>#帕金森综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48538, encryptionId=de2a485385f, topicName=帕金森综合征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43d925986347, createdName=12498f1em16(暂无昵称), createdTime=Fri Dec 15 01:39:00 CST 2017, time=2017-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917789, encodeId=1d37191e78937, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Mar 02 10:39:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2023497, encodeId=7122202349e86, content=<a href='/topic/show?id=57ce9605ef6' target=_blank style='color:#2F92EE;'>#重要作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96057, encryptionId=57ce9605ef6, topicName=重要作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Tue May 01 00:39:00 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767325, encodeId=78b31e673255a, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Sun Apr 01 15:39:00 CST 2018, time=2018-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421122, encodeId=64c71421122f0, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Mon Nov 20 07:39:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431017, encodeId=f8cf143101e5b, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Mon Nov 20 07:39:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1603573, encodeId=8d2616035e355, content=<a href='/topic/show?id=83d1e7588bb' target=_blank style='color:#2F92EE;'>#线粒体功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77588, encryptionId=83d1e7588bb, topicName=线粒体功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=927419051757, createdName=ylz8409, createdTime=Mon Nov 20 07:39:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262405, encodeId=c36a262405a6, content=帕金森与线粒体功能障碍, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Sun Nov 19 00:50:56 CST 2017, time=2017-11-19, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1677180, encodeId=7dff16e718071, content=<a href='/topic/show?id=d31ce7585bb' target=_blank style='color:#2F92EE;'>#线粒体功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77585, encryptionId=d31ce7585bb, topicName=线粒体功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=92f027457982, createdName=xuruicheng, createdTime=Sun Dec 10 05:39:00 CST 2017, time=2017-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665725, encodeId=3a9c1665e25ed, content=<a href='/topic/show?id=de2a485385f' target=_blank style='color:#2F92EE;'>#帕金森综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48538, encryptionId=de2a485385f, topicName=帕金森综合征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43d925986347, createdName=12498f1em16(暂无昵称), createdTime=Fri Dec 15 01:39:00 CST 2017, time=2017-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917789, encodeId=1d37191e78937, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Mar 02 10:39:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2023497, encodeId=7122202349e86, content=<a href='/topic/show?id=57ce9605ef6' target=_blank style='color:#2F92EE;'>#重要作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96057, encryptionId=57ce9605ef6, topicName=重要作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Tue May 01 00:39:00 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767325, encodeId=78b31e673255a, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Sun Apr 01 15:39:00 CST 2018, time=2018-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421122, encodeId=64c71421122f0, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Mon Nov 20 07:39:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431017, encodeId=f8cf143101e5b, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Mon Nov 20 07:39:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1603573, encodeId=8d2616035e355, content=<a href='/topic/show?id=83d1e7588bb' target=_blank style='color:#2F92EE;'>#线粒体功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77588, encryptionId=83d1e7588bb, topicName=线粒体功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=927419051757, createdName=ylz8409, createdTime=Mon Nov 20 07:39:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262405, encodeId=c36a262405a6, content=帕金森与线粒体功能障碍, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Sun Nov 19 00:50:56 CST 2017, time=2017-11-19, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1677180, encodeId=7dff16e718071, content=<a href='/topic/show?id=d31ce7585bb' target=_blank style='color:#2F92EE;'>#线粒体功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77585, encryptionId=d31ce7585bb, topicName=线粒体功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=92f027457982, createdName=xuruicheng, createdTime=Sun Dec 10 05:39:00 CST 2017, time=2017-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665725, encodeId=3a9c1665e25ed, content=<a href='/topic/show?id=de2a485385f' target=_blank style='color:#2F92EE;'>#帕金森综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48538, encryptionId=de2a485385f, topicName=帕金森综合征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43d925986347, createdName=12498f1em16(暂无昵称), createdTime=Fri Dec 15 01:39:00 CST 2017, time=2017-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917789, encodeId=1d37191e78937, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Mar 02 10:39:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2023497, encodeId=7122202349e86, content=<a href='/topic/show?id=57ce9605ef6' target=_blank style='color:#2F92EE;'>#重要作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96057, encryptionId=57ce9605ef6, topicName=重要作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Tue May 01 00:39:00 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767325, encodeId=78b31e673255a, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Sun Apr 01 15:39:00 CST 2018, time=2018-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421122, encodeId=64c71421122f0, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Mon Nov 20 07:39:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431017, encodeId=f8cf143101e5b, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Mon Nov 20 07:39:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1603573, encodeId=8d2616035e355, content=<a href='/topic/show?id=83d1e7588bb' target=_blank style='color:#2F92EE;'>#线粒体功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77588, encryptionId=83d1e7588bb, topicName=线粒体功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=927419051757, createdName=ylz8409, createdTime=Mon Nov 20 07:39:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262405, encodeId=c36a262405a6, content=帕金森与线粒体功能障碍, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Sun Nov 19 00:50:56 CST 2017, time=2017-11-19, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1677180, encodeId=7dff16e718071, content=<a href='/topic/show?id=d31ce7585bb' target=_blank style='color:#2F92EE;'>#线粒体功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77585, encryptionId=d31ce7585bb, topicName=线粒体功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=92f027457982, createdName=xuruicheng, createdTime=Sun Dec 10 05:39:00 CST 2017, time=2017-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665725, encodeId=3a9c1665e25ed, content=<a href='/topic/show?id=de2a485385f' target=_blank style='color:#2F92EE;'>#帕金森综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48538, encryptionId=de2a485385f, topicName=帕金森综合征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43d925986347, createdName=12498f1em16(暂无昵称), createdTime=Fri Dec 15 01:39:00 CST 2017, time=2017-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917789, encodeId=1d37191e78937, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Mar 02 10:39:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2023497, encodeId=7122202349e86, content=<a href='/topic/show?id=57ce9605ef6' target=_blank style='color:#2F92EE;'>#重要作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96057, encryptionId=57ce9605ef6, topicName=重要作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Tue May 01 00:39:00 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767325, encodeId=78b31e673255a, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Sun Apr 01 15:39:00 CST 2018, time=2018-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421122, encodeId=64c71421122f0, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Mon Nov 20 07:39:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431017, encodeId=f8cf143101e5b, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Mon Nov 20 07:39:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1603573, encodeId=8d2616035e355, content=<a href='/topic/show?id=83d1e7588bb' target=_blank style='color:#2F92EE;'>#线粒体功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77588, encryptionId=83d1e7588bb, topicName=线粒体功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=927419051757, createdName=ylz8409, createdTime=Mon Nov 20 07:39:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262405, encodeId=c36a262405a6, content=帕金森与线粒体功能障碍, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Sun Nov 19 00:50:56 CST 2017, time=2017-11-19, status=1, ipAttribution=)]
    2017-11-19 sunfeifeiyang

    帕金森与线粒体功能障碍

    0

相关资讯

Radiology:功能性脑连接及帕金森病病变严重程度的关系

帕金森病(PD)又名震颤麻痹,是最常见的神经退行性疾病之一。流行病学显示,患病率为15~328/10万人口,>65岁人群约1%;发病率为10~21/10万人口/年。PD病因及发病机制尚未明确,可能与社会因素、药物因素、患者因素等有关。PD病理改变为:中脑黑质致密部、蓝斑神经元色素脱失,黑质色素变淡及出现路易小体。PD神经生化改变为:中脑黑质致密部、蓝斑神经元脱失致上述部位及其神经末梢处多巴胺(DA

老树开新花!金刚烷胺新用途获FDA批准

帕金森病(PD)是一种常见的慢性神经退行性疾病,伴随治疗药物的使用,产生的运动障碍也成为了众多帕金森患者的困扰。克服运动障碍对于PD患者来说,不仅是身体的解放,更是心理上的一种解放。帕金森病人的福音来了。近日,美国食品和药物管理局(FDA)批准金刚烷胺(amantadine,曾用名ADS-5102)缓释胶囊用于治疗在接受左旋多巴治疗的PD患者的运动障碍。

Radiology:扫个磁共振患者老是动怎么办?

本研究旨在轻度认知障碍(MCI)、帕金森病(PD)和中老年健康志愿者进行实时校正3Dγ氨基丁酸MR波谱成像中比较不可抗拒头部运动、频率及B0变化、对数据质量的影响,并将结果发表在Radiology上。

Radiology:也许PD患者出现视幻觉后预示着疾病的进展

为了通过分析全脑静息态功能连接来更好的理解帕金森病(PD)患者出现视幻觉(VHs)的病理生理机制,对合并VH的PD(PD +VH)患者、无VH的PD (PD - VH)患者和健康志愿者进行研究,并将结果发表在Radiology上。

The Lancet:糖尿病药物或可用于治疗帕金森病

伦敦大学学院领导的一项新研究发现,通常用于治疗糖尿病的药物艾塞那肽可能具有改善帕金森病的潜力。该研究发表The Lancet期刊上,研究发现,帕金森病患者每周注射艾塞那肽,持续1年后运动能力出现改善。

Mayo Clin Proc:肉毒毒素能否改善帕金森病震颤和患者感觉?

2017年9月,发表在《Mayo Clin Proc》上的一项双盲、安慰剂-对照、交叉试验,调查了肉毒毒素对帕金森病(PD)震颤的治疗效果。试验结果表明:在临床范围内,经个性化方式注射肉毒毒素(IncoA)能改善PD震颤和患者感觉,手无力发生率显着较低。